Novel biomarkers and emerging therapeutic strategies in testicular germ cell tumors

The diagnostic and treatment landscape for patients with Testicular Germ-Cell Tumors (TGCTs) is evolving. The discovery of two novel biomarkers, MicroRNA-371a-3p (miR-371) and circulating tumor DNA (ctDNA), have shown promise in initial studies and appear to offer superior sensitivity and specificity over conventional tumor markers. In patients with progressive disease after salvage and/or high-dose chemotherapy (HDCT), treatment options remain limited. While immune-checkpoint inhibition in this patient population has shown limited efficacy, several new therapeutic strategies have emerged with the most notable one being the targeting of Claudin-6 (CLDN6). Here, we will highlight recent advances with miR-371 and ctDNA, review their potential role in the initial diagnosis, minimal residual disease (MRD) assessment, and discuss their role as a prognostic biomarker. We will review the recent and ongoing efforts to improve survival outcomes in patients with refractory TGCTs including immune-checkpoint and CD30 inhibition, recent efforts with cabozantinib, CLDN6 inhibition and the role of maintenance chemotherapy with or without tyrosine kinase inhibition (TKIs) in patients after HDCT.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1913935
Primary Topic
Testicular diseases and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Novel biomarkers and emerging therapeutic strategies in testicular germ cell tumors

Tareq Salous, Ahmed Bilal Khalid
Frontiers in Oncology
Testicular diseases and treatments
article

Novel biomarkers and emerging therapeutic strategies in testicular germ cell tumors

Tareq Salous, Ahmed Bilal Khalid
article en

Abstract

The diagnostic and treatment landscape for patients with Testicular Germ-Cell Tumors (TGCTs) is evolving. The discovery of two novel biomarkers, MicroRNA-371a-3p (miR-371) and circulating tumor DNA (ctDNA), have shown promise in initial studies and appear to offer superior sensitivity and specificity over conventional tumor markers. In patients with progressive disease after salvage and/or high-dose chemotherapy (HDCT), treatment options remain limited. While immune-checkpoint inhibition in this patient population has shown limited efficacy, several new therapeutic strategies have emerged with the most notable one being the targeting of Claudin-6 (CLDN6). Here, we will highlight recent advances with miR-371 and ctDNA, review their potential role in the initial diagnosis, minimal residual disease (MRD) assessment, and discuss their role as a prognostic biomarker. We will review the recent and ongoing efforts to improve survival outcomes in patients with refractory TGCTs including immune-checkpoint and CD30 inhibition, recent efforts with cabozantinib, CLDN6 inhibition and the role of maintenance chemotherapy with or without tyrosine kinase inhibition (TKIs) in patients after HDCT.

Frontiers in OncologyVol. 16
Emory University (US), Winship Cancer Institute (US), Indiana University School of Medicine (US)
Good health and well-being
Testicular diseases and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon